Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

This study is testing whether adding an immunotherapy drug (toripalimab) to standard maintenance chemotherapy (capecitabine) after initial treatment works better than capecitabine alone for high-risk nasopharyngeal carcinoma (a type of head and neck cancer). **You may be eligible if...** - You are between 18 and 70 years old with confirmed nasopharyngeal carcinoma - Your cancer is classified as high-risk (advanced lymph node spread, certain virus markers, or specific features) - You have already received induction chemotherapy plus concurrent chemoradiation - Your blood counts, liver, kidney, and organ function are adequate **You may NOT be eligible if...** - Your cancer has spread (recurrent or metastatic disease) - You have a history of another malignancy in the past 5 years - You have had prior immunotherapy or other conflicting treatments - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.